HPC
BMRN icon

HM Payson & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

HM Payson & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-500
Closed -$28.2K – 1147
2026
Q1 		$28.2K Buy
+500
New +$29.2K ﹤0.01% 794
2023
Q3 		– Sell
-60
Closed -$5.2K – 1002
2023
Q2 		$5.2K Buy
+60
New +$5.65K ﹤0.01% 854
2020
Q4 		– Sell
-38
Closed -$3K – 1091
2020
Q3 		$3K Buy
+38
New +$3.85K ﹤0.01% 913

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

HM Payson & Co's BMRN Position: Q2 2026 in Review

HM Payson & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2026, closing a stake of 500 shares — an estimated $28.2K sold.

HM Payson & Co first reported a position in BMRN in Q3 2020 and held it in 3 quarters. The position peaked at $28.2K in Q1 2026. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • HM Payson & Co reported no remaining BioMarin Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • HM Payson & Co sold 500 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $28.2K.
  • HM Payson & Co first reported a position in BioMarin Pharmaceuticals in Q3 2020 and held it in 3 quarters.
  • HM Payson & Co's BioMarin Pharmaceuticals position peaked at $28.2K in Q1 2026.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on HM Payson & Co's 13F filing for Q2 2026, filed 17 Jul 2026.